Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
New Treatment for Paediatric Crohn's Disease Now Available in the UK

MAIDENHEAD, England, January 16, 2013 /PRNewswire/ --

HUMIRA® (adalimumab) is the first biologic treatment in more than five years to be approved in the European Union for the treatment of severe active paediatric Crohn's disease offering at-home administration after suitable training[1],[2]

AbbVie announced today that HUMIRA® (adalimumab) is now available for the treatment of paediatric patients aged six to 17 years with severe active Crohn's disease (CD) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications to such therapies. [1]

"Paediatric Crohn's disease is a chronic bowel disease that may have a significant impact on a child or young person and his or her family's quality of life," said Dr Richard Russell, Consultant Paediatric Gastroenterologist, Royal Hospital for Sick Children, Glasgow. "The number of children and young people diagnosed with Crohn's disease continues to rise in the UK but the number of treatment options available remains limited. For patients who do not respond to standard therapies, this new treatment option addresses a significant unmet need by offering the flexibility of out of hospital injectable administration, usually by patients or their parents."  

Paediatric Crohn's disease is a chronic condition of the gastrointestinal (GI) tract. In the UK there are currently around 90,000 people living with Crohn's disease, which can affect people of all ages, including children.[3]

As a type of inflammatory bowel disease, it most commonly involves the end of the small intestine and the beginning of the large intestine.[3] In addition to symptoms such as abdominal pain, weight loss and diarrhoea, paediatric Crohn's disease can affect children in several ways unique to this age group, including delayed growth and/or puberty.[4]

Richard Driscoll, Chief Executive of Crohn's and Colitis UK a charity which provides information, support and research for people of all ages affected by inflammatory bowel disease, said "Paediatric Crohn's disease is known to be increasing in frequency among children and young adults of all ages. We welcome this new treatment that is being made available in the UK as the symptoms can be very severe and have a significant debilitating effect on the child and their family."

"Whilst the psychological effects cannot be measured, symptoms, treatment and side effects may mean that childhood and adolescence can be severely disrupted making it difficult for some children to cope emotionally. Physical growth and pubertal development can be delayed, creating an additional problem, particularly in relation to school, college and social life" said Rod Mitchell, Chairman of the Crohn's in Childhood Research Association (CICRA).

Notes to editors

About HUMIRA[1]

HUMIRA® (adalimumab) is a prescription medicine licenced for the treatment of moderate to severe active rheumatoid arthritis, active polyarticular juvenile idiopathic arthritis, active and progressive psoriatic arthritis, severe active ankylosing spondylitis (AS), severe axial spondyloarthritis without radiographic evidence of AS, moderately to severely active Crohn's disease and ulcerative colitis in adults, severe active Crohn's disease in paediatric patients, and moderate to severe chronic plaque psoriasis. Please refer to the Humira Summary of Product Characteristics (SmPC) for full product information which can be found at http://www.medicines.org.uk.

Adverse events should be reported. Reporting forms and information can be found at  http://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AbbVie Ltd on +44-(0)1628-774933.

About AbbVie

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients live healthier lives and collaborate on sustainable healthcare solutions. In 2013, AbbVie will employ approximately 23,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit http://www.abbvie.co.uk

1.    Humira Summary of Product Characteristics accessed via http://www.medicines.org.uk

2.    European Medicines Agency. Scientific discussion. 2007. Available from: http://www.rcplondon.ac.uk/sites/default/files/documents/national-paediatric-uk-ibd-inpatient-care-audit-report-round-3_0.pdf Last accessed December 2012

3.    NHS CHOICES. Crohn's disease. Available from: http://www.nhs.uk/conditions/crohns-disease/Pages/Introduction.aspx Last accessed December 2012

4.    Mackner, L (2003). "Review: Psychosocial Issues in Pediatric Inflammatory Bowel Disease" J. Pediatr Psychol. 29 (4): 243-257


About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
The recent trends like cloud computing, social, mobile and Internet of Things are forcing enterprises to modernize in order to compete in the competitive globalized markets. However, enterprises are approaching newer technologies with a more silo-ed way, gaining only sub optimal ...
The 16th International Cloud Expo announces that its Call for Papers is now open. 16th International Cloud Expo, to be held June 9–11, 2015, at the Javits Center in New York City brings together Cloud Computing, APM, APIs, Security, Big Data, Internet of Things, DevOps and WebRTC...
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the c...
AppZero, a fast, flexible way to move enterprise applications to the cloud, has announced that AppZero Cloud Edition is available to try on Amazon Web Services (AWS) free of charge, as an AWS Test Drive. AppZero's award-winning application migration tool enables users to move se...
Internet of @ThingsExpo announced today a limited time free "Expo Plus" registration option. On site registration price of $600 will be set to 'free' for delegates who register during this Labor Day week. To take advantage of this opportunity, attendees can use the coupon code "I...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE